polyarcturus
Well-Known Member
i think its possible, i have a grower friend she didnt smoke for 3 months, piss tested, showed positive. she was never a big smoker to begin so to me thats conclusive.
Can you get high by touching weed??? I feel it!!! :-/
- Thread starter brewing up
- Start date
Gastanker
Well-Known Member
This is a double post but even scientists agree you can absorb it through the skin...
Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin - http://www.ncbi.nlm.nih.gov/pubmed/15927811
Summary
Background:
Cannabinoid receptors mediate the psychopharmacological action of marijuana and have been localized in the central and peripheral nervous system as well as on cells of the immune system.
Objective:
Up to now, two cannabinoid receptors (CB1 and CB2) have been cloned and recent studies on animal tissue gave evidence for the presence of cannabinoid receptors in the skin.
Methods:
In the present immunohistochemical investigation we determined the precise localization of CB1 and CB2 in sections of human skin and in one case of mastocytosis.
Results:
CB1 and CB2 immunoreactivity was observed in cutaneous nerve fiber bundles, mast cells, macrophages, epidermal keratinocytes, and the epithelial cells of hair follicles, sebocytes and eccrine sweat glands. In epidermal keratinocytes, hair follicle and sebaceous glands, CB1 and CB2 were distributed in a complementary fashion. Double-immunostaining with an anti-CGRP antibody suggested the presence of cannabinoid receptors on small afferent peptidergic nerves.
Conclusion:
The abundant distribution of cannabinoid receptors on skin nerve fibers and mast cells provides implications for an anti-inflammatory, anti-nociceptive action of cannabinoid receptor agonists and suggests their putatively broad therapeutic potential.
Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin - http://www.ncbi.nlm.nih.gov/pubmed/15927811
Summary
Background:
Cannabinoid receptors mediate the psychopharmacological action of marijuana and have been localized in the central and peripheral nervous system as well as on cells of the immune system.
Objective:
Up to now, two cannabinoid receptors (CB1 and CB2) have been cloned and recent studies on animal tissue gave evidence for the presence of cannabinoid receptors in the skin.
Methods:
In the present immunohistochemical investigation we determined the precise localization of CB1 and CB2 in sections of human skin and in one case of mastocytosis.
Results:
CB1 and CB2 immunoreactivity was observed in cutaneous nerve fiber bundles, mast cells, macrophages, epidermal keratinocytes, and the epithelial cells of hair follicles, sebocytes and eccrine sweat glands. In epidermal keratinocytes, hair follicle and sebaceous glands, CB1 and CB2 were distributed in a complementary fashion. Double-immunostaining with an anti-CGRP antibody suggested the presence of cannabinoid receptors on small afferent peptidergic nerves.
Conclusion:
The abundant distribution of cannabinoid receptors on skin nerve fibers and mast cells provides implications for an anti-inflammatory, anti-nociceptive action of cannabinoid receptor agonists and suggests their putatively broad therapeutic potential.
Gastanker
Well-Known Member
Here's another scholarly article: http://www.ingentaconnect.com/content/adis/add/2004/00000002/00000004/art00003
Abstract:
The two main modes of cannabinoid administration, oral ingestion of tetrahydrocannabinol (THC) and smoking of dry cannabis plant material, both have specific advantages and disadvantages. Disadvantages of oral ingestion include slow and erratic absorption, delayed onset of action and low systemic bioavailability, whereas disadvantages of smoking include mucosal damage and short duration of effect. In recent years several new modes of cannabinoid delivery have been tested. Alternative routes of systemic pulmonary administration include inhalation with a vaporizer and the use of cannabinoids in aerosol form. They avoid or reduce the formation of carcinogenic combustion products found in cannabis smoke. Sublingual (buccal) administration of liquid cannabis extracts has been tested in clinical trials in the UK. This mode is easy to administer and might enable easier dose titration than oral capsules. Transdermal delivery achieves a sustained and steadier action than inhalation or oral administration of THC, and is being investigated in preclinical studies by groups in the US and Israel. Use of ethosomal carriers has been shown to enhance skin permeation by the lipophilic cannabinoids. Rectal administration of THC-hemisuccinate suppositories has been tested in some patients; systemic bioavailability is twice as high as with oral administration because of the reduced first-pass effect. Water-soluble agonists to the cannabinoid receptor that allow intravenous administration have been developed. Dexanabinol, a non-psychotropic neuroprotective cannabinoid derivative, was given intravenously in clinical studies to decrease the consequences of severe closed head injuries. Increasing water solubility, for example by the use of cyclodextrin technology, also improved the possibilities of topical cannabinoid administration to the eye for glaucoma treatment. Several of these new approaches to cannabinoid delivery now under preclinical and clinical investigation may find their way into clinical practice within a few years.
Huh a transdermal cannabinoid patch? For those that don't know transdermal means through the skin.
Abstract:
The two main modes of cannabinoid administration, oral ingestion of tetrahydrocannabinol (THC) and smoking of dry cannabis plant material, both have specific advantages and disadvantages. Disadvantages of oral ingestion include slow and erratic absorption, delayed onset of action and low systemic bioavailability, whereas disadvantages of smoking include mucosal damage and short duration of effect. In recent years several new modes of cannabinoid delivery have been tested. Alternative routes of systemic pulmonary administration include inhalation with a vaporizer and the use of cannabinoids in aerosol form. They avoid or reduce the formation of carcinogenic combustion products found in cannabis smoke. Sublingual (buccal) administration of liquid cannabis extracts has been tested in clinical trials in the UK. This mode is easy to administer and might enable easier dose titration than oral capsules. Transdermal delivery achieves a sustained and steadier action than inhalation or oral administration of THC, and is being investigated in preclinical studies by groups in the US and Israel. Use of ethosomal carriers has been shown to enhance skin permeation by the lipophilic cannabinoids. Rectal administration of THC-hemisuccinate suppositories has been tested in some patients; systemic bioavailability is twice as high as with oral administration because of the reduced first-pass effect. Water-soluble agonists to the cannabinoid receptor that allow intravenous administration have been developed. Dexanabinol, a non-psychotropic neuroprotective cannabinoid derivative, was given intravenously in clinical studies to decrease the consequences of severe closed head injuries. Increasing water solubility, for example by the use of cyclodextrin technology, also improved the possibilities of topical cannabinoid administration to the eye for glaucoma treatment. Several of these new approaches to cannabinoid delivery now under preclinical and clinical investigation may find their way into clinical practice within a few years.
Huh a transdermal cannabinoid patch? For those that don't know transdermal means through the skin.
Gastanker
Well-Known Member
Lets see how many scientist we can find that must be flat out crazy. Here's another few: http://www.ingentaconnect.com/content/adis/cpk/2003/00000042/00000004/art00003
Abstract:
[SUP]9[/SUP]-Tetrahydrocannabinol (THC) is the main source of the pharmacological effects caused by the consumption of cannabis, both the marijuana-like action and the medicinal benefits of the plant. However, its acid metabolite THC-COOH, the non-psychotropic cannabidiol (CBD), several cannabinoid analogues and newly discovered modulators of the endogenous cannabinoid system are also promising candidates for clinical research and therapeutic uses. Cannabinoids exert many effects through activation of G-protein-coupled cannabinoid receptors in the brain and peripheral tissues. Additionally, there is evidence for non-receptor-dependent mechanisms.Natural cannabis products and single cannabinoids are usually inhaled or taken orally; the rectal route, sublingual administration, transdermal delivery, eye drops and aerosols have only been used in a few studies and are of little relevance in practice today. The pharmacokinetics of THC vary as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes, psychotropic effects start within seconds to a few minutes, reach a maximum after 15-30 minutes, and taper off within 2-3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30-90 minutes, reach their maximum after 2-3 hours and last for about 4-12 hours, depending on dose and specific effect.At doses exceeding the psychotropic threshold, ingestion of cannabis usually causes enhanced well-being and relaxation with an intensification of ordinary sensory experiences. The most important acute adverse effects caused by overdosing are anxiety and panic attacks, and with regard to somatic effects increased heart rate and changes in blood pressure. Regular use of cannabis may lead to dependency and to a mild withdrawal syndrome. The existence and the intensity of possible long-term adverse effects on psyche and cognition, immune system, fertility and pregnancy remain controversial. They are reported to be low in humans and do not preclude legitimate therapeutic use of cannabis-based drugs.Properties of cannabis that might be of therapeutic use include analgesia, muscle relaxation, immunosuppression, sedation, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and induction of apoptosis in cancer cells.
And another: http://www.ingentaconnect.com/content/apl/lddi/2010/00000036/00000009/art00009
Abstract:
Context: The nonpsychoactive cannabinoid, cannabidiol (CBD), has great potential for the treatment of chronic and `breakthrough' pain that may occur in certain conditions like cancer. To fulfill this goal, suitable noninvasive drug delivery systems need to be developed for CBD. Chronic pain relief can be best achieved through the transdermal route, whereas `breakthrough' pain can be best alleviated with intranasal (IN) delivery. Combining IN and transdermal delivery for CBD may serve to provide patient needs-driven treatment in the form of a nonaddictive nonopioid therapy. Objective: Herein we have evaluated the IN and transdermal delivery of CBD with and without permeation enhancers. Materials and Methods: In vivo studies in rats and guinea pigs were carried out to assess nasal and transdermal permeation, respectively. Results: CBD was absorbed intranasally within 10 minutes with a bioavailability of 34-46%, except with 100% polyethylene glycol formulation in rats. Bioavailability did not improve with enhancers. The steady-state plasma concentration of CBD in guinea pigs after transdermal gel application was 6.3 ± 2.1 ng/mL, which was attained at 15.5 ± 11.7 hours. The achievement of a significant steady-state plasma concentration indicates that CBD is useful for chronic pain treatment through this route of administration. The steady-state concentration increased by 3.7-fold in the presence of enhancer. A good in vitro and in vivo correlation existed for transdermal studies. Conclusion: The results of this study indicated that CBD could be successfully delivered through the IN and transdermal routes.
Another patent:
Abstract of EP1186298
A transdermal structure (10) is provided for delivering cannabis chemical(s) (14) to one's bloodstream. The structure comprises a backing layer (11) which carries the cannabis chemical(s). The chemicals are contained in a film (35) on the backing layer or within a cavity (12) formed in the backing layer. Alternatively, an opening (43) in a secondary layer (42) that overlies the backing layer may be used to create the cavity. The structure is applied to one's skin so that the cannabis chemicals are in contact with the skin. A polymer material (22) which is mixed with the cannabis and placed in the cavity or a membrane over the cavity may be used to control the flow of cannabis chemical(s) into the bloodstream. In an alternative embodiment, a porous material (34) impregnated with cannabis chemical(s) may be used to hold the chemical(s) in the cavity. Because of the relatively slow transdermal flow rate of cannabis materials, it is preferred to utilize permeation enhancers in conjunction with the cannabis carrier or reservoir matrixes or skin contacting adhesive layers (13)
Heres a great one http://onlinelibrary.wiley.com/doi/10.1211/0022357022791/abstract
Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol
ABSTRACT
The purpose of this study was to quantify the in-vitro human skin transdermal flux of Δ[SUP]8[/SUP]-tetrahydrocannabinol (Δ[SUP]8[/SUP]-THC), cannabidiol (CBD) and cannabinol (CBN). These cannabinoids are of interest because they are likely candidates for transdermal combination therapy. Differential thermal analysis and in-vitro diffusion studies with human tissue were completed for the compounds. Heats of fusion, melting points and relative thermodynamic activities were determined for the crystalline compounds, CBD and CBN. Flux, permeability, tissue concentration and lag times were measured in the diffusion experiments. CBN had a lower heat of fusion and corresponding higher calculated relative thermodynamic activity than CBD. Ethanol concentrations of 30 to 33% significantly increased the transdermal flux of Δ[SUP]8[/SUP]-THC and CBD. Tissue concentrations of Δ[SUP]8[/SUP]-THC were significantly higher than for CBN. Lag times for CBD were significantly smaller than for CBN. The permeabilities of CBD and CBN were 10-fold higher than for Δ[SUP]8[/SUP]-THC. Combinations of these cannabinoids with ethanol will be further studied in transdermal patch formulations in vitro and in vivo, as significant flux levels of all the drugs were obtained. CBD, the most polar of the three drugs, and other more polar cannabinoids will also be the focus of future drug design studies for improved transdermal delivery rates.
Papers all day long...
Topical preparations and topical delivery systems
Among the most widely known drugs with peripheral effects are nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, capsaicin, alpha-adrenoreceptor antagonists, and cannabinoids. However, not all medications applied topically on the skin have peripheral action. Topically applied opioids predominantly have a central effect. Therefore, one can didactically distinguish transdermal medication such as buprenorphine and fentanyl and topical drugs acting locally, which have a primary role on the peripheral nervous system and decrease of nociceptive afferents (Figures 1 and ​and22).3
Even the Ancient Egyptians...
Seriously, look at an analysis.
Abstract:
And another: http://www.ingentaconnect.com/content/apl/lddi/2010/00000036/00000009/art00009
Abstract:
Context: The nonpsychoactive cannabinoid, cannabidiol (CBD), has great potential for the treatment of chronic and `breakthrough' pain that may occur in certain conditions like cancer. To fulfill this goal, suitable noninvasive drug delivery systems need to be developed for CBD. Chronic pain relief can be best achieved through the transdermal route, whereas `breakthrough' pain can be best alleviated with intranasal (IN) delivery. Combining IN and transdermal delivery for CBD may serve to provide patient needs-driven treatment in the form of a nonaddictive nonopioid therapy. Objective: Herein we have evaluated the IN and transdermal delivery of CBD with and without permeation enhancers. Materials and Methods: In vivo studies in rats and guinea pigs were carried out to assess nasal and transdermal permeation, respectively. Results: CBD was absorbed intranasally within 10 minutes with a bioavailability of 34-46%, except with 100% polyethylene glycol formulation in rats. Bioavailability did not improve with enhancers. The steady-state plasma concentration of CBD in guinea pigs after transdermal gel application was 6.3 ± 2.1 ng/mL, which was attained at 15.5 ± 11.7 hours. The achievement of a significant steady-state plasma concentration indicates that CBD is useful for chronic pain treatment through this route of administration. The steady-state concentration increased by 3.7-fold in the presence of enhancer. A good in vitro and in vivo correlation existed for transdermal studies. Conclusion: The results of this study indicated that CBD could be successfully delivered through the IN and transdermal routes.
Another patent:
Abstract of EP1186298
A transdermal structure (10) is provided for delivering cannabis chemical(s) (14) to one's bloodstream. The structure comprises a backing layer (11) which carries the cannabis chemical(s). The chemicals are contained in a film (35) on the backing layer or within a cavity (12) formed in the backing layer. Alternatively, an opening (43) in a secondary layer (42) that overlies the backing layer may be used to create the cavity. The structure is applied to one's skin so that the cannabis chemicals are in contact with the skin. A polymer material (22) which is mixed with the cannabis and placed in the cavity or a membrane over the cavity may be used to control the flow of cannabis chemical(s) into the bloodstream. In an alternative embodiment, a porous material (34) impregnated with cannabis chemical(s) may be used to hold the chemical(s) in the cavity. Because of the relatively slow transdermal flow rate of cannabis materials, it is preferred to utilize permeation enhancers in conjunction with the cannabis carrier or reservoir matrixes or skin contacting adhesive layers (13)
Heres a great one http://onlinelibrary.wiley.com/doi/10.1211/0022357022791/abstract
Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol
ABSTRACT
The purpose of this study was to quantify the in-vitro human skin transdermal flux of Δ[SUP]8[/SUP]-tetrahydrocannabinol (Δ[SUP]8[/SUP]-THC), cannabidiol (CBD) and cannabinol (CBN). These cannabinoids are of interest because they are likely candidates for transdermal combination therapy. Differential thermal analysis and in-vitro diffusion studies with human tissue were completed for the compounds. Heats of fusion, melting points and relative thermodynamic activities were determined for the crystalline compounds, CBD and CBN. Flux, permeability, tissue concentration and lag times were measured in the diffusion experiments. CBN had a lower heat of fusion and corresponding higher calculated relative thermodynamic activity than CBD. Ethanol concentrations of 30 to 33% significantly increased the transdermal flux of Δ[SUP]8[/SUP]-THC and CBD. Tissue concentrations of Δ[SUP]8[/SUP]-THC were significantly higher than for CBN. Lag times for CBD were significantly smaller than for CBN. The permeabilities of CBD and CBN were 10-fold higher than for Δ[SUP]8[/SUP]-THC. Combinations of these cannabinoids with ethanol will be further studied in transdermal patch formulations in vitro and in vivo, as significant flux levels of all the drugs were obtained. CBD, the most polar of the three drugs, and other more polar cannabinoids will also be the focus of future drug design studies for improved transdermal delivery rates.
Papers all day long...
Topical preparations and topical delivery systems
Among the most widely known drugs with peripheral effects are nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, capsaicin, alpha-adrenoreceptor antagonists, and cannabinoids. However, not all medications applied topically on the skin have peripheral action. Topically applied opioids predominantly have a central effect. Therefore, one can didactically distinguish transdermal medication such as buprenorphine and fentanyl and topical drugs acting locally, which have a primary role on the peripheral nervous system and decrease of nociceptive afferents (Figures 1 and ​and22).3
Even the Ancient Egyptians...
They say you can absorb cannabinoids and specifically THC which is present in raw bud... Again, there is active THC as well as less active THCA in raw bud
reppinhigh22
Active Member
Where in any of those 3 posts does it say that you can absorb Raw fresh weed into your skin? xD
Its known that you can use tincture and other things that are for use through the skin. However, all of those the cannabis has to be heated to a certain point to fully activate it.
Its known that you can use tincture and other things that are for use through the skin. However, all of those the cannabis has to be heated to a certain point to fully activate it.
Mr.Marijuana420
Well-Known Member
all throughout the season last year i was on probation. i wasnt smoking at all bc my term was soon ending, every day id be up there touching my buds and tying up braches, and so on, nvr came up in a drug test, also ur theory about tolerance, harvest was about 2 weeks after my term ended, and my tolerance was still very low, and i sat for 8 hrs all night trimming. it got to a point where, id just space out and forget what im doing and come back to chopping half the bud off(thats when i know its time to go to sleep), now is this bc i was "stoned" from handling my bud, bc im sure some would perceive it like that. or merely bc i sat in one spot doing a continueous mindless task for a long period of time. bc thats what i attribute it to, more or less exaustion, bc i didnt feel stoned in the least bit, just out of it, if anyone has ever stayed up for a period of 2 days(im sure a few have) thats what its similar to, ur mind is so exausted it starts to disconnect from reality, and tries to shut down to rest
Gastanker
Well-Known Member
No THC in pot... really? Again? Where are you guys getting this?
I swear people need to do at least a tiny amount of digging before stating "facts" they heard when they were 12 from the neighborhood stoner:
This is from the following 187 page scientific paper on Cannabis:
Here it states that there is both free THC as well as THCA in the samples they collected:
They did multiple different separations and tests for cannabinioid content, here is one of them that involves no heat.
I don't think they made this all up... if so that's a ton of referenced fiction
By all means don't take my word for it but at least listen to the scientists over fellow stoners.
Another one -
Abstract -
Cannabinoid acids readily decarboxylate to the corresponding cannabinoid. Methods are available for the determination of Δ[SUP]9[/SUP]-tetrahydrocannabinol (THC) and its acids (THCA) and published data on the levels of these compounds in cannabis are summarized. Using gas and liquid chromatography, fresh cannabis (64 samples) and cannabis resin (26 samples) from different countries were examined. Wide variations in the relative amounts of THCA and THC in cannabis were found. For cannabis resin, a wide range of values was also found (0·5: 1 to 6·1: 1), the lower values being in resins from the Indian sub-continent and the higher values in resins from the Mediterranean area. Total THC values were in the range 1·–10·6% in cannabis and 6·0–12·5% in cannabis resin.
I swear people need to do at least a tiny amount of digging before stating "facts" they heard when they were 12 from the neighborhood stoner:
This is from the following 187 page scientific paper on Cannabis:
Here it states that there is both free THC as well as THCA in the samples they collected:
They did multiple different separations and tests for cannabinioid content, here is one of them that involves no heat.
I don't think they made this all up... if so that's a ton of referenced fiction
By all means don't take my word for it but at least listen to the scientists over fellow stoners.
Another one -
Abstract -
Cannabinoid acids readily decarboxylate to the corresponding cannabinoid. Methods are available for the determination of Δ[SUP]9[/SUP]-tetrahydrocannabinol (THC) and its acids (THCA) and published data on the levels of these compounds in cannabis are summarized. Using gas and liquid chromatography, fresh cannabis (64 samples) and cannabis resin (26 samples) from different countries were examined. Wide variations in the relative amounts of THCA and THC in cannabis were found. For cannabis resin, a wide range of values was also found (0·5: 1 to 6·1: 1), the lower values being in resins from the Indian sub-continent and the higher values in resins from the Mediterranean area. Total THC values were in the range 1·–10·6% in cannabis and 6·0–12·5% in cannabis resin.
MuckyDucky
Well-Known Member
Just smelling my finger when I trim makes me smile.
Weed-noob
Active Member
Hahahahahaha hahahaha
haloman420
Well-Known Member
I felt pretty damn high trimming a couple pounds without smoking. No gloves.
Mr.Marijuana420
Well-Known Member
Ive passed probation tests after fingering around checking for mold for days before, so thats a no, THC, and other cannabinoids arent water soluble
Mr.Marijuana420
Well-Known Member
Old thread.. shit
Forgetowash
Member
Pretty certain you can get high from eating weed.
rawweedyoumoron
New Member
You need to de-carb THCA to activate the delta THC which gets you high. That takes temperatures like he described. Eating raw cannibus with THCA won't do it. All psychoactive edibles are pre-processed de-carbed / heated RAW cannibus in order to activate that THC delta compound. Surprised no one stood up to you until now.
Also these studies ignore the fact that when testing for the THC they were using pg/mg not ng/mg (a huge drastic difference in detectable potency) and THCA isn't going to activate or metabolize into the THC delta in a human body (we lack that heat potential). Most drug tests test for THC delta metabolites. My main guess right now, haven't looked - is that the Germany study that started all this was paid for and promoted by a drug test manufacturer to test for THCA in addition to THC delta and that's why their study is focusing on that, and that alone. In the USA and most countries, nothings changed, they will test you on a ng/mg scale in the metabolites from THC delta, not A. You can't get that from handling RAW cannibus, inhaling RAW cannibus by smell (turpines) or any non-de-carbed form of RAW cannibus. FACTS.
lusidghost
Well-Known Member
These types of threads are always from 2012. I blame the Mayans.
meangreengrowinmachine
Well-Known Member
You are replying to a year old comment my man lolz
PadawanWarrior
Well-Known Member
Just smelling my weed gives me a head rush a lot of times. Terpenes to the brain, 
rawweedyoumoron
New Member
Just smelling my weed gives me a head rush a lot of times. Terpenes to the brain,
almost 2! lol I didn't really look just knew it couldn't stand, because duh...